A phosphorylated antigen and antibody at Ser23 site of PGAM1 protein and preparation method and application thereof

By designing and preparing phosphorylated antigens and antibodies at the Ser23 site of PGAM1 protein, the problem of lack of specific antigens in the prior art is solved, the research and clinical application of phosphorylation modification of PGAM1 protein is achieved, and the accuracy of diagnosis and treatment is improved. sex.

CN118185914BActive Publication Date: 2024-11-29TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410226783.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-02-29
Publication Date
2024-11-29
Estimated Expiration
2044-02-29

AI Technical Summary

Technical Problem

The lack of antigens specifically phosphorylated to the Ser23 site of the PGAM1 protein in the prior art has hindered the functional analysis of PGAM1 protein and the study of related molecular mechanisms, especially in the diagnosis and treatment of diseases such as tumors.

Method used

By designing specific phosphorylated antigens and antibodies for PGAM1 protein, the best antigens are screened using the immunoepitope database, and phosphorylated antigens and antibodies are obtained through phosphorylation and protein coupling, for the preparation of for tumors, autoimmune diseases and Cardiovascular system diseases related agents.

Benefits of technology

Provides highly specific phosphorylated antibodies to help study the mechanism of the phosphorylation modification of PGAM1 protein in biological events, and provides potential targets for the diagnosis and treatment of clinical diseases, improving the accuracy of detection of PGAM1 protein phosphorylation levels sex.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118185914B_ABST
    Figure CN118185914B_ABST
Patent Text Reader

Abstract

The present application relates to the field of biotechnology, and in particular to a phosphorylated antigen and antibody at the Ser23 site of a PGAM1 protein, and a preparation method and application thereof; the phosphorylated antigen is a phosphorylated polypeptide, the amino acid sequence of the phosphorylated polypeptide is shown in SEQ ID NO.1, and the phosphorylation site of the phosphorylated polypeptide is serine; a phosphorylated antibody with good specificity can be prepared by using the phosphorylated antigen, and thus the phosphorylated antigen provided by the present application fills the gap in the prior art in that there is no specific phosphorylated antigen at the Ser23 site of a PGAM1 protein.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of biotechnology, and in particular to a phosphorylated antigen and antibody at the Ser23 site of a PGAM1 protein, and a preparation method and application thereof. Background Art

[0002] Phosphoglycerate mutase 1 (PGAM1) is an important functional enzyme in the glycolysis pathway. Its main function is to catalyze the conversion of 3-phosphoglycerate (3-PG) to 2-phosphoglycerate (2-PG) to promote glucose metabolism and energy production, and coordinate serine production and pentose phosphate pathway. PGAM1 is mainly expressed in the liver, kidney, and brain, and is abnormally expressed in a variety of human tumors such as breast cancer, colorectal cancer, lung cancer, prostate cancer, oral squamous cell carcinoma, and esophageal squamous cell carcinoma. This abnormal expression can promote the proliferation and metastasis of cancer cells, leading to poor prognosis.

[0003] Post-translational modifications such as phosphorylation, ubiquitination, and sumoylation play an important regulatory role in physiological and pathological processes mediated by cell signaling pathways. PGAM1 plays an important role in aerobic glycolysis and cell metabolic reprogramming, so further research on the post-translational modification of PGAM1 protein is of great significance. Based on previous studies, the 23rd serine (Ser23) in the amino acid sequence of PGAM1 is the site of protein phosphorylation modification, which may play an important role in regulating the function of PGAM1 protein and upstream and downstream signal transduction.

[0004] Antibodies are important tools for studying protein functions and have been widely used in the study of the pathogenesis of autoimmune diseases, infectious diseases, tumors, disease diagnosis, and clinical treatment. However, there is currently no specific phosphorylated PGAM1 S23 antibody available, which seriously hinders the functional analysis of PGAM1 protein and related molecular mechanism research. The specificity of antibodies mainly depends on the antigen, so how to provide a specific phosphorylated antigen of the Ser23 site of the PGAM1 protein. Summary of the invention

[0005] The present application provides a phosphorylated antigen at Ser23 site of PGAM1 protein, an antibody, and a preparation method and application thereof, so as to fill the gap in the prior art in that there is no specific phosphorylated antigen at Ser23 site of PGAM1 protein.

[0006] In a first aspect, the present application provides a phosphorylated antigen of the Ser23 site of the PGAM1 protein, wherein the phosphorylated antigen is a phosphorylated polypeptide, and the amino acid sequence of the phosphorylated polypeptide is shown in SEQ ID NO.1, wherein the phosphorylation site of the phosphorylated polypeptide is serine.

[0007] Optionally, the phosphorylation site of the phosphorylated polypeptide is site 23 of the PGAM1 protein.

[0008] In a second aspect, the present application provides a method for preparing the phosphorylated antigen described in the first aspect, the method comprising:

[0009] Taking site 23 of the PGAM1 protein as a base point, a preset number of amino acid groups are selected along the upstream or downstream direction on the amino acid sequence of the PGAM1 protein as shown in SEQ ID NO. 2 to obtain multiple groups of preset antigens;

[0010] Using an immune epitope database to analyze and screen multiple groups of preset antigens to obtain the best antigen;

[0011] Phosphorylating the optimal antigen to obtain a phosphorylated polypeptide;

[0012] Performing protein coupling on the phosphorylated polypeptide to obtain a phosphorylated antigen;

[0013] The preset number is 2 to 5.

[0014] In a fourth aspect, the present application provides an application of a phosphorylated antigen at the Ser23 site of the PGAM1 protein, wherein the application includes using the phosphorylated antigen described in the first aspect to prepare pharmaceutical agents related to tumors, autoimmune diseases, and cardiovascular diseases, wherein the related pharmaceutical agents include pharmaceutical preparations used for diagnosis, treatment, and prognosis.

[0015] In a fifth aspect, the present application provides a phosphorylated antibody against Ser23 site of PGAM1 protein, wherein the phosphorylated antibody is obtained by immunizing an animal body with the phosphorylated antigen described in the first aspect.

[0016] In a sixth aspect, the present application provides a method for preparing the phosphorylated antibody according to the fourth aspect, the method comprising:

[0017] Immunizing an animal model with the phosphorylated antigen described in the first aspect to a preset antiserum titer to obtain an antiserum sample;

[0018] According to the amino acid sequence of the PGAM1 protein shown in SEQ ID NO.2, a phosphorylated polypeptide: NRFS(p)GWY and a non-phosphorylated polypeptide: NRFSGWY were synthesized respectively, and then protein coupling was performed to obtain phosphorylated antigen and non-phosphorylated antigen;

[0019] The antiserum sample is purified using the phosphorylated antigen and the non-phosphorylated antigen to obtain the phosphorylated antibody.

[0020] Optionally, the preset antiserum titer is ≥1:32000.

[0021] Optionally, the number of immunizations is ≥ 4 times.

[0022] Optionally, the step of purifying the antiserum sample using the phosphorylated antigen and the non-phosphorylated antigen to obtain the phosphorylated antibody comprises the following steps:

[0023] Using the phosphorylated antigen to affinity purify the antiserum sample once to obtain a crude phosphorylated antibody;

[0024] The crude phosphorylated antibody is subjected to secondary affinity purification using the non-phosphorylated antigen to obtain the phosphorylated antibody.

[0025] In the seventh aspect, the present application provides an application of a phosphorylated antibody at the Ser23 site of the PGAM1 protein, wherein the application includes using the phosphorylated antibody described in the fifth aspect to prepare pharmaceutical agents related to tumors, autoimmune diseases, and cardiovascular diseases, wherein the related pharmaceutical agents include pharmaceutical preparations used for diagnosis, treatment, and prognosis.

[0026] The above technical solution provided by the embodiment of the present application has the following advantages compared with the prior art:

[0027] The present application provides a phosphorylated antigen at Ser23 of the PGAM1 protein. The phosphorylation analysis of the amino acid sequence of the PGAM1 protein, combined with the specific analysis of the PGAM1 protein, can clearly show that the 23rd site of the PGAM1 protein is a key site for phosphorylation modification. At the same time, this site may play an important role in regulating the function of the PGAM1 protein and upstream and downstream signal transduction. Therefore, a specific phosphorylated antigen of the PGAM1 protein can be obtained by specifically designing this site. At the same time, the specific amino acid sequence of the phosphorylated antigen can be refined, and a phosphorylated antibody with good specificity can be prepared through the phosphorylated antigen, which is helpful for studying PGA The invention discloses the mechanism of action of phosphorylation modification of specific sites of M1 protein in specific biological events or the occurrence and development of diseases, and can also provide potential targets for the diagnosis and treatment of clinical diseases, and can also improve the accuracy of detecting the phosphorylation level of PGAM1 protein using immunology-related experiments such as IHC and ELISA; at the same time, the phosphorylated antigen can also be used to explore the relationship between PGAM1 and autoimmune diseases, infectious diseases, tumors and other diseases, and has broad application prospects in disease diagnosis, treatment and prognosis determination; therefore, the phosphorylated antigen provided in the present application fills the gap in the prior art that there is no specific phosphorylated antigen at the Ser23 site of PGAM1 protein. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments consistent with the present application and, together with the description, serve to explain the principles of the present application.

[0029] In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, for ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative labor.

[0030] Figure 1 A detailed schematic diagram of a method for preparing a phosphorylated antigen at the Ser23 site of the PGAM1 protein provided in an embodiment of the present application;

[0031] Figure 2 A schematic diagram of a method for preparing a phosphorylated antibody against Ser23 of PGAM1 protein provided in an embodiment of the present application;

[0032] Figure 3 A detailed schematic diagram of a method for preparing a phosphorylated antibody against Ser23 of PGAM1 protein provided in an embodiment of the present application;

[0033] Figure 4A schematic diagram of the actual process of a method for preparing a phosphorylated antibody against Ser23 of PGAM1 protein provided in an embodiment of the present application;

[0034] Figure 5 This is a graph showing the immunogenicity assessment results of the phosphorylated polypeptide provided in Example 1 of the present application;

[0035] Figure 6 This is a diagram showing the hydrophilicity evaluation results of the amino acid sequence of the phosphorylated polypeptide provided in Example 1 of the present application;

[0036] Figure 7 This is a graph showing the results of mass spectrometry and high performance liquid chromatography detection of phosphorylated polypeptides provided in Example 1 of the present application, wherein: Figure 7 a is the mass spectrometry detection result of phosphorylated peptides. Figure 7 b is a graph showing the results of HPLC detection of phosphorylated peptides;

[0037] Figure 8 This is a graph showing the results of mass spectrometry and high performance liquid chromatography of the non-phosphorylated polypeptide provided in Example 1 of the present application, wherein: Figure 8 a is the mass spectrometry detection result of non-phosphorylated peptide. Figure 8 b is a graph showing the results of HPLC detection of non-phosphorylated peptides;

[0038] Fig. 9 This is a graph showing the results of ELISA detection of phospho-peptide antigen and non-phosphorylated polypeptide antigen by the purified PGAM1 S23 phosphorylated antibody provided in Example 3 of the present application;

[0039] Fig.10 This is a graph showing the specificity of the PGAM1 S23 phosphorylation antibody verified by Western blotting technology as provided in Example 4 of the present application. DETAILED DESCRIPTION

[0040] In order to make the purpose, technical solution and advantages of the embodiments of the present application clearer, the technical solution in the embodiments of the present application will be clearly and completely described below in conjunction with the drawings in the embodiments of the present application. Obviously, the described embodiments are part of the embodiments of the present application, not all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of this application.

[0041] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in this application can be purchased from the market or prepared by existing methods.

[0042] The embodiment of the present application provides a phosphorylated antigen at the Ser23 site of the PGAM1 protein, wherein the phosphorylated antigen is a phosphorylated polypeptide, and the amino acid sequence of the phosphorylated polypeptide is shown in SEQ ID NO.1, wherein the phosphorylation site of the phosphorylated polypeptide is serine.

[0043] In some optional embodiments, the phosphorylation site of the phosphorylated polypeptide is site 23 of the PGAM1 protein.

[0044] In the examples of the present application, by clarifying the specific phosphorylation site of the phosphorylated polypeptide, the key phosphorylation modification site in the PGAM1 protein can be clarified. Since the 23rd site of the PGAM1 protein may play an important role in regulating the function of the PGAM1 protein and upstream and downstream signal transduction, a specific design is performed for this site, and a specific antigen for the PGAM1 protein can be clearly obtained, so as to obtain a specific antibody for the PGAM1 protein in the future.

[0045] It should be noted that the gene sequence of the PGAM1 protein can be Gene ID: 5223.

[0046] It should be noted that the amino acid sequence of the PGAM1 protein may be the amino acid sequence shown in SEQ ID NO.2.

[0047] Figure 1 The detailed process diagram of a method for preparing a phosphorylated antigen at the Ser23 site of the PGAM1 protein provided in an embodiment of the present application is exemplified;

[0048] like Figure 1 As shown, based on a general inventive concept, an embodiment of the present application provides a method for preparing the phosphorylated antigen, the method comprising:.

[0049] S1. Taking the 23rd site of the PGAM1 protein as the base point, a preset number of amino acid groups are selected along the upstream or downstream direction on the amino acid sequence of the PGAM1 protein as shown in SEQ ID NO.2 to obtain multiple groups of preset antigens;

[0050] S2. Analyze and screen multiple groups of preset antigens using an immune epitope database to obtain the best antigen;

[0051] S3. phosphorylating the optimal antigen to obtain a phosphorylated polypeptide;

[0052] S4. performing protein coupling on the phosphorylated polypeptide to obtain a phosphorylated antigen;

[0053] The preset number is 2 to 5.

[0054] In the examples of the present application, the specific steps of phosphorylation modification and protein coupling are refined. First, multiple amino acid groups are selected and matched based on the 23rd site of the PGAM1 protein to design multiple groups of preset antigens. Then, these preset antigens are analyzed and screened through the immune epitope database to obtain the best antigen with the best data. Finally, this best antigen is phosphorylated and protein-coupled to obtain a phosphorylated antigen.

[0055] The preset number can be 2, 3, 4 or 5.

[0056] Based on a general inventive concept, an embodiment of the present application provides an application of a phosphorylated antigen at the Ser23 site of the PGAM1 protein, wherein the application includes using the phosphorylated antigen to prepare pharmaceutical agents related to tumors, autoimmune diseases, and cardiovascular diseases, wherein the related pharmaceutical agents include pharmaceutical preparations used for diagnosis, treatment, and prognosis.

[0057] This application is realized based on the above-mentioned phosphorylated antigen. The specific steps of phosphorylating the antigen can refer to the above-mentioned embodiment. Since this application adopts part or all of the technical solutions of the above-mentioned embodiment, it has at least all the beneficial effects brought by the technical solutions of the above-mentioned embodiment, which will not be repeated here one by one.

[0058] Based on a general inventive concept, an embodiment of the present application provides a phosphorylated antibody against Ser23 of PGAM1 protein, wherein the phosphorylated antibody is obtained by immunizing an animal body with the phosphorylated antigen.

[0059] The phosphorylated antibody is realized based on the phosphorylated antigen. The specific steps of phosphorylating the antigen can refer to the above embodiment. Since the phosphorylated antibody adopts part or all of the technical solutions of the above embodiment, it has at least all the beneficial effects brought by the technical solutions of the above embodiment, which will not be repeated here.

[0060] Figure 2 The schematic diagram of the process for preparing a phosphorylated antibody of Ser23 site of PGAM1 protein provided in the embodiment of the present application is exemplified;

[0061] like Figure 2 As shown, based on a general inventive concept, the present application embodiment provides a method for preparing the phosphorylated antibody, the method comprising:

[0062] S1. Immunizing an animal model with the phosphorylated antigen to a preset antiserum titer to obtain an antiserum sample;

[0063] S2. According to the amino acid sequence of the PGAM1 protein shown in SEQ ID NO.2, a phosphorylated polypeptide: NRFS(p)GWY and a non-phosphorylated polypeptide: NRFSGWY are synthesized respectively, and then protein coupling is performed to obtain phosphorylated antigen and non-phosphorylated antigen;

[0064] S3. Purify the antiserum sample using the phosphorylated antigen and the non-phosphorylated antigen respectively to obtain the phosphorylated antibody.

[0065] The preparation method is a preparation method for the above-mentioned phosphorylated antibody. The specific composition of the phosphorylated antibody can refer to the above-mentioned embodiment. Since the preparation method adopts part or all of the technical solutions of the above-mentioned embodiment, it at least has all the beneficial effects brought by the technical solutions of the above-mentioned embodiment, which will not be repeated here one by one.

[0066] It should be noted that the preset antiserum titer can be detected by an indirect ELISA method.

[0067] It should be noted that the purification method can be carried out by antigen-antibody affinity purification.

[0068] In some optional embodiments, the preset antiserum titer is ≥1:32000.

[0069] In some optional embodiments, the number of immunizations is ≥ 4 times.

[0070] In the implementation of the present application, by controlling the specific number of immunizations and the specific preset antiserum titer, the antiserum titer in the animal model can reach 1:32000 or above through multiple immunizations, thereby making it clear that the phosphorylated antibody has good specificity.

[0071] Figure 3 The detailed process diagram of a method for preparing a phosphorylated antibody of the Ser23 site of the PGAM1 protein provided in an embodiment of the present application is exemplified;

[0072] like Figure 3 As shown, in some optional embodiments, the antiserum sample is purified using the phosphorylated antigen and the non-phosphorylated antigen to obtain the phosphorylated antibody, comprising the steps of:

[0073] S301. Affinity purifying the antiserum sample using the phosphorylated antigen to obtain a crude phosphorylated antibody;

[0074] S302. Using the non-phosphorylated antigen, the crude phosphorylated antibody is subjected to secondary affinity purification to obtain the phosphorylated antibody.

[0075] In the embodiments of the present application, by refining the specific steps of purification, multiple affinity purifications are carried out on the antiserum samples in sequence using non-phosphorylated antigens and phosphorylated antigens, so that the antiserum samples can be initially purified by non-phosphorylated antigens, and then the antiserum samples can be further purified by phosphorylated antigens, so that specific antibodies can be obtained.

[0076] Based on a general inventive concept, an embodiment of the present application provides an application of a phosphorylation antibody at the Ser23 site of the PGAM1 protein, wherein the application includes using the phosphorylated antibody to prepare pharmaceutical agents related to tumors, autoimmune diseases, and cardiovascular diseases, wherein the related pharmaceutical agents include pharmaceutical preparations used for diagnosis, treatment, and prognosis.

[0077] The present application will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are intended only to illustrate the present application and are not intended to limit the scope of the present application. The experimental methods for which specific conditions are not specified in the following examples are usually measured according to industry standards. If there is no corresponding industry standard, then the conditions recommended by the manufacturer are followed.

[0078] Example 1

[0079] Figure 4 The actual process diagram of a method for preparing a phosphorylated antibody of the Ser23 site of the PGAM1 protein provided in an embodiment of the present application is exemplified;

[0080] like Figure 4 As shown, first, preparing the phosphorylated antigen peptide at Ser23 site of PGAM1 protein, the specific steps include:

[0081] 1. First, the amino acid sequence of PGAM1 was obtained from the NCBI database, as shown in SEQ ID NO.2.

[0082] MAAYKLVLIRHGESAWNLENRFSGWYDADLSPAGHEEAKRGGQALRDAGYEFDICFTSVQKRAIRTLWTVLDAIDQMWLPVVRTWRLNERHYGGLTGLNKAETAAKHGEAQVKIWRRSYDVPPPPMEPD HPFYSNISKDRRYADLTEDQLPSCESLKDTIARALPFWNEEIVPQIKEGKRVLIAAHGNSLRGIVKHLEGLSEEAIMELNLPTGIPIVYELDKNLKPIKPMQFLGDEETVRKAMEAVAAQGKAKK(SEQ ID NO.2).

[0083] Taking the Ser23 site of PGAM1 protein as the center, the N-terminus is adjacent to three PGAM1 amino acid sequences, the C-terminus is connected to three amino acid sequences, a phosphorylation group is added to the amino acid Ser23 to obtain the optimal antigen as shown in SEQ ID NO.1, and then it is phosphorylated to obtain the phosphorylated polypeptide sequence: NRFS(p)GWY.

[0084] 2. The immunogenicity and hydrophilicity of the antigen peptide sequence NRFS(p)GWY were evaluated using the Immune Epitope Database (IEDB). The results are as follows: Figure 5 and Figure 6 As shown, the results were all good, indicating that NRFS(p)GWY has the potential to develop antigenic peptides.

[0085] 3. According to the design of the hapten synthetic peptide, a phosphorylation group was added to the Ser23 site to obtain the phosphorylated antigen (phosphorylated polypeptide), and then the quality of the synthetic phosphorylated polypeptide was detected by HPLC and MASS, such as Figure 7 As shown, it shows that the synthesized phosphorylated polypeptide sequence is correct, and the purity is greater than 90%, and the total amount meets the requirements. Subsequently, the phosphorylated polypeptide is coupled with hemocyanin (KLH) to obtain the whole antigen, and then the whole antigen is used for immunization of rabbits (pSer23-KLH);

[0086] Correspondingly, a non-phosphorylated polypeptide sequence corresponding to Ser23 was synthesized according to the amino acid sequence shown in SEQ ID NO.1: NRFSGWY, and then the quality of the synthesized peptide was detected by HPLC and MASS, such as Figure 8 As shown, it shows that the sequence of the synthesized non-phosphorylated polypeptide is correct, and the purity is greater than 90%, and the total amount meets the requirements; each polypeptide is packaged and stored in a -80°C refrigerator for subsequent antibody purification steps.

[0087] Example 2

[0088] 2. Preparation of antiserum using the full antigen pSer23-KLH according to the multi-point immunization rabbit method

[0089] 1. Preparation of negative serum:

[0090] The experiment selected healthy female New Zealand white rabbits, 4 months old, with an average weight of 2.1 kg, and injected at multiple points on the back. 3 mL of blood was collected from the ear vein of the New Zealand white rabbit used for injection into a blood collection tube, and hemostasis was stopped by pressing with a cotton ball; the blood was then placed at room temperature for about 1 hour, and the blood was allowed to coagulate to form a blood clot, and then placed at 4°C for 2 hours to allow the serum to precipitate, centrifuged at 3000 rpm for 15 minutes, and the supernatant was aspirated, marked as negative control serum, and packaged and stored at -80°C for testing.

[0091] 2. Animal immunization (total time is about 49 days):

[0092] (1) Dissolve the pSer23-KLH antigen polypeptide powder in sterile 1×PBS, draw the antigen solution with a sterile syringe, draw an equal amount of Freund's complete adjuvant (CFA) with another syringe, connect the two with a plastic tube, and pump back and forth repeatedly to mix the pSer23-KLH peptide with CFA until a completely emulsified emulsion is formed. Drop it in water and it will not spread (the first main injection uses Freund's complete adjuvant, and the subsequent booster injections use Freund's incomplete adjuvant, both of which are fully mixed with an equal volume of antigen before injection);

[0093] (2) The first immunization was performed by subcutaneous injection on both sides of the thin and loose skin of the neck and back, intramuscular injection on both sides of the gluteal muscles and thighs, intradermal injection on both sides of the waist, injection on the rabbit paw pads, etc. The antigen emulsion was injected at multiple sites and multiple points. The first main injection dose was 1.6 mg antigen polypeptide / rabbit;

[0094] (3) A second booster immunization was performed 14 days after the first immunization. Freund's incomplete adjuvant (IFA) was used instead of CFA as the immune adjuvant to prepare the antigen emulsion and injected in the same manner as the first immunization. 0.8 mg of antigen polypeptide was injected per experimental rabbit for booster injection;

[0095] (4) A third booster immunization was performed 28 days after the first immunization. Freund's incomplete adjuvant (IFA) was used instead of CFA as the immune adjuvant to prepare the antigen emulsion and injected in the same manner as the first immunization. The total amount of antigen in this booster immunization was about 0.8 mg.

[0096] (5) Blood collection after the third booster immunization: On the 29th day, 1 mL of blood was collected from the ear vein. The blood was placed at room temperature for about 1 hour. After the blood coagulated and formed a blood clot, it was placed at 4°C for 2 hours to allow the serum to precipitate. The blood was centrifuged at 3000 rpm for 15 minutes, and the supernatant was aspirated. The antiserum titer was tested by ELISA.

[0097] (6) The fourth booster immunization was carried out 42 days after the first immunization. The immunization antigen was Freund's incomplete adjuvant + pSer23-KLH antigen polypeptide. Elisa test was performed after the fourth immunization. If the titer reached 256K or above, the rabbit was finally released. If the titer did not reach 256K, 6 to 7 more injections were given.

[0098] (7) Final bloodletting: On the 49th day, the titer of the antiserum tested by ELISA reached the requirement, and whole blood was collected from the carotid artery. The beaker used to collect the blood was sealed and left to stand at room temperature overnight to allow the blood clot to shrink. The next day, the precipitated serum was dispensed into 50 mL centrifuge tubes under aseptic operation, centrifuged at 3000 rpm for 15 min, and the supernatant was taken and dispensed into 1 mL / tube, labeled as post-immune antiserum (about 51 mL in total), and stored at -80°C.

[0099] Embodiment 3:

[0100] 3. Antiserum purification, preparation of affinity purified antibodies and ELISA titer detection

[0101] (1) The phosphorylated antigen polypeptide pSer23 and the non-phosphorylated antigen polypeptide Ser23 prepared in Example 1 were respectively coupled to bovine serum albumin (BSA) by the glutaraldehyde method and used as fillers pSer23-BSA and Ser23-BSA of affinity purification chromatography columns;

[0102] (2) Preparation of phosphorylated synthetic peptide chromatography column and non-phosphorylated synthetic peptide chromatography column: Dissolve pSer23-BSA and Ser23-BSA in coupling buffer, with the concentration of 0.7 mg / mL. Take 7 mg of pSer23-BSA and Ser23-BSA solution and add them to 5 mL of resin, mix well and add them to the chromatography column and mix well at room temperature for 15 minutes. Place the chromatography column upright at room temperature for 30 minutes, remove the caps at the upper and lower ends of the chromatography column, collect the outflowing liquid, and rinse the column with 3 times the volume of resin coupling buffer. Cover the bottom cover of the chromatography column, add 50mM L-Cysteine ​​HCl to the coupling buffer, mix well, and then add an equal volume of buffer to the chromatography column. Mix well at room temperature for 15min, let it stand for 30min, then remove the bottom cover to release the coupling buffer, wash the chromatography column with 6 volumes of 1M NaCl, and then rinse the chromatography column with 2 volumes of storage buffer, cover the cover, add 1 volume of storage buffer, and store at 4℃ for later use;

[0103] (3) Incubate 10 mL of antiserum with the affinity purification column overnight. Pre-wash with HCl at pH 5.0 to remove impurities; then elute with 0.15 Mglycine (pH 2.5) buffer and quickly neutralize with 10x PBS buffer to prepare affinity purified antibodies;

[0104] (4) passing the affinity purified antibody through a non-phosphorylation affinity adsorption column to remove antibodies against non-phosphorylated polypeptides and obtain phosphorylation site-specific antibodies;

[0105] The concentration of purified antibody was detected by Bradford method. The results are shown in Table 1.

[0106] Table 1 Concentration of each purified antibody

[0107] project Concentration (ng / ml) Volume(ml) Mass (mg) M21129-A(remove non-modification) 0.417 6 2.502 M21130-B(remove non-modification) 0.292 6 1.752 M21131-C(remove non-modification) 0.313 6 1.878 M21132-D (remove non-modification) 0.298 6 1.788

[0108] As shown in Table 1, the yield of affinity purified antibodies is normal.

[0109] 4. Affinity purification antibody ELISA titer detection:

[0110] (1) Antigen coating: The phosphorylated antigen peptide pSer23 and the non-phosphorylated antigen peptide Ser23 were diluted to 6 μg / mL with 0.05 mol / L carbonate (pH = 9.6), 100 μL / well, and incubated at 4°C overnight;

[0111] (2) Washing the plate: Wash the plate three times with 0.05% Tween-20 (PBST), 3 min each time;

[0112] (3) Blocking: Add 150 μl of 5% skim milk powder (PBST) to each well and block at 37°C for 60 min;

[0113] (4) Washing the plate: Wash three times with 0.05% Tween-20 (PBST), 3 min each time;

[0114] (5) Adding primary antibody: dilute the affinity purified antibody at 1:1000, then dilute in equal proportions, and incubate at 37°C for 1 h;

[0115] (6) Washing the plate: Wash three times with 0.05% Tween-20 (PBST), 3 min each time;

[0116] (7) Add secondary antibody: horseradish enzyme-labeled goat anti-rabbit IgG (H+L), catalog number: 116154, antibody company: Jackson. Dilute at a volume ratio of 1:8000 and incubate at 37°C for 45 min;

[0117] (8) Washing the plate: Wash the plate five times with 0.05% Tween-20 (PBST), 3 min each time;

[0118] (9) Color development: Add 100 μL / well of substrate solution (TMB), react for 5 min to 10 min, and finally add 100 μL of 2 mol / L sulfuric acid to terminate the reaction;

[0119] (10) OD value measurement: The OD value was measured at a wavelength of 450 nm using an enzyme marker. The results are shown in Table 2 and Fig. 9 shown.

[0120] Table 2 Affinity purification antibody ELISA titer test results

[0121] BLANK 1K 3K 9K 27K 81K 243K 729K M21129-A (non-modified) 0.035 0.044 0.042 0.04 0.041 0.04 0.033 0.039 M21129-B (non-modified) 0.037 0.036 0.036 0.04 0.04 0.042 0.04 0.04 M21129-C (non-modified) 0.032 0.071 0.04 0.038 0.027 0.044 0.039 0.038 M21129-D (non-modified) 0.033 0.043 0.038 0.037 0.037 0.037 0.058 0.043 M21129-A (phosphorylation modification) 0.036 0.976 0.361 0.167 0.082 0.061 0.04 0.034 M21130-B (phosphorylation modification) 0.036 0.478 0.326 0.244 0.077 0.0g6 0.066 0.04 M21131-C (phosphorylation modification) 0.038 0.534 0.201 0.194 0.067 0.053 0.058 0.042 M21132-D (phosphorylation modification) 0.039 0.41 0.167 0.085 0.062 0.051 0.082 0.042

[0122] Example 4

[0123] 5. Application of PGAM1 protein Ser23 phosphorylation antibody in Western blot experiment:

[0124] The highly specific phosphorylation antibody against Ser23 of PGAM1 protein prepared in the present application can be used to detect the difference in phosphorylation levels of cells by Western blot experiment. The specific steps include:

[0125] (1) 293T cells were transfected with the PGAM1 Ser23 phosphorylation inactivation mutant plasmid PGAM1 S23-mut and the PGAM1 Ser23 phosphorylation activation mutant plasmid PGAM1 S23-TG; 48 hours later, cell proteins were extracted and cells were lysed at 4°C using RIPA Lysis Buffer. The cell lysate was centrifuged at 12,000 rpm for 20 min at 4°C, the supernatant was transferred to a new EP tube, 5× SDS loading buffer was added, and the tube was boiled at 100°C for 10 min. To prevent protein degradation, the operation was performed on ice as much as possible.

[0126] (2) SDS-PAGE electrophoresis (polyacrylamide gel electrophoresis): Clamp the glass plate with polyacrylamide gel as needed, quickly add the prepared 12% concentration SDS polyacrylamide separation gel into the gap of the glass plate to 2 / 3 of the glass plate, and seal the gel with isopropanol. After the separation gel solidifies, pour out the isopropanol and absorb the residual liquid with filter paper. Add the prepared 5% mass concentration stacking gel to the separation gel and immediately insert the comb. After the gel is completely solidified, pull out the comb and rinse the sample wells with water. Fix the electrophoresis device, add Tris-glycine electrophoresis buffer, and add 20μL of sample and pre-stained marker in sequence. Connect the electrophoresis device to the power supply, adjust the voltage to 80V, and when bromophenol blue runs to the separation gel, adjust the voltage to 110V until bromophenol blue runs to the bottom of the separation gel, and turn off the power;

[0127] (3) Transfer: Remove the gel, remove the accumulated gel and excess parts, and completely soak it in the newly prepared transfer buffer; cut 4 pieces of filter paper and 1 PVDF membrane of the same size as the gel, and make a mark on one corner of the membrane with a pencil; soak the PVDF membrane in 100% methanol for about 1 minute to activate the PVDF membrane, and then soak it in transfer buffer; lay the cathode plate of the transfer device flat, place a layer of sponge soaked in transfer buffer, and neatly place two layers of filter paper soaked in transfer buffer on the sponge, and use a glass rod to drive out bubbles; place the transfer clip with the black side facing down in the transfer buffer, and place the black sponge, two layers of filter paper, gel, membrane (activated with methanol for 1 minute in advance, mark the front and back in the upper right corner, and the reverse side is attached to the membrane), two layers of filter paper and black sponge in order from bottom to top, ensuring that there are no bubbles between the membrane and the gel and that they are completely attached; clamp the gel with a transfer clip. Place the fixed transfer clip into the transfer tank, fill the transfer tank with transfer solution, and finally place the transfer tank in a foam box filled with ice. Transfer the membrane for 2.5 hours at a constant current of 180mA (black to black, red to red, pay attention to the direction of the electrodes);

[0128] (4) Blocking: Take out the electroporated PVDF membrane, wash it once with TBST, and block it with 5% milk on a shaker at room temperature for 1 h;

[0129] (5) Primary antibody incubation: dilute the PGAM1 protein Ser23 phosphorylation antibody 1:1000 with primary antibody diluent; remove the blocked PVDF membrane, rinse with TBST for 2 minutes, and then incubate in the primary antibody at 4°C overnight (16 hours)

[0130] (6) Washing: Wash with TBST 5 times, 5 min each time;

[0131] (7) Secondary antibody incubation: Place the PVDF membrane in a horseradish peroxidase-labeled secondary antibody (1:5000) diluted in 5% milk and incubate on a shaker at room temperature for 1 h.

[0132] (8) Washing: Wash with TBST 5 times, 5 min each time;

[0133] (9) Development: Mix ECL AB solution in a volume ratio of 1:1 (0.5 mL each), pour evenly onto the PVDF membrane, and wet and dry the color development box with clean toilet paper. Place the membrane in the box and remove bubbles. After 5 minutes of color development, take it to a dark room, cut a film of corresponding size and stick it on the membrane. Determine the exposure time according to the fluorescence intensity.

[0134] (10) After developing the film, place it in the developer for 1-3 minutes, rinse it with clean water, place it in the fixer for about 9 minutes, and finally dry it in an oven. Determine the target band based on the marker and analyze the results.

[0135] Test results such as Fig.10 As shown, this indicates that in the immunoprecipitation product, the Ser23 site phosphorylation antibody (PGAM1S23) can recognize the PGAM1 protein in the phosphorylated state at Ser23 site, but cannot recognize the PGAM1 protein in the non-phosphorylated state at Ser23 site, proving that the phosphorylation antibody has good specificity.

[0136] In summary, the phosphorylated antigen at the Ser23 site of the PGAM1 protein provided in the embodiment of the present application can be used to prepare a phosphorylated antibody with good specificity. Therefore, the phosphorylated antigen provided in the present application fills the gap in the prior art that there is no specific phosphorylated antigen at the Ser23 site of the PGAM1 protein.

[0137] At the same time, the embodiments of the present application provide a phosphorylation antibody for the Ser23 site of the PGAM1 protein. In practical applications, the phosphorylation antibody is convenient for studying the correlation between the phosphorylation modification of a specific site of the PGAM1 protein and specific biological events such as immune cell activation, cell metabolic reprogramming, and cell cycle.

[0138] At the same time, the phosphorylation antibody of the Ser23 site of the PGAM1 protein provided in the embodiment of the present application can also be used to study the phosphorylation polyclonal antibody of the Ser23 site of the PGAM1 protein, which is helpful to explore the various biological functions of the PGAM1 protein.

[0139] In addition, a phosphorylation antibody against the Ser23 site of the PGAM1 protein provided in the embodiments of the present application is helpful to explore the mechanism of action of phosphorylation modification of the PGAM1 protein in the occurrence and development of autoimmune diseases, infectious diseases, tumors and other diseases, and can also be used to evaluate changes in tumor metabolic levels under different treatment conditions, providing potential targets for the diagnosis and treatment of clinical tumor diseases.

[0140] Various embodiments of the present application may be presented in the form of a range; it should be understood that the description in the form of a range is only for convenience and brevity, and should not be understood as a rigid limitation on the scope of the present application; therefore, the range description should be considered to have specifically disclosed all possible sub-ranges and single numerical values ​​within the range. For example, the range description from 1 to 6 should be considered to have specifically disclosed sub-ranges, such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., as well as single numbers within the range, such as 1, 2, 3, 4, 5 and 6, which apply regardless of the range. In addition, whenever a numerical range is indicated herein, it is meant to include any cited number (fractional or integer) within the indicated range.

[0141] In the present application, in the absence of any contrary description, the directional words used, such as "upper" and "lower", are specifically the directions of the drawings in the accompanying drawings. In addition, in the description of the present specification, the terms "including", "comprising", etc. refer to "including but not limited to". In this article, relational terms such as "first" and "second" are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply that there is any such actual relationship or order between these entities or operations. In this article, "and / or" describes the association relationship of the associated objects, indicating that there may be three relationships, for example, A and / or B, which can represent: A exists alone, A and B exist at the same time, and B exists alone. Wherein A, B can be singular or plural. In this article, "at least one" refers to one or more, and "plural" refers to two or more. "At least one", "at least one of the following" or similar expressions refer to any combination of these items, including any combination of singular or plural items. For example, "at least one of a, b, or c", or "at least one of a, b and c", can both mean: a, b, c, ab (i.e. a and b), ac, bc or abc, where a, b, c can be single or plural, respectively.

[0142] The above description is only a specific implementation of the present application, so that those skilled in the art can understand or implement the present application. Various modifications to these embodiments will be apparent to those skilled in the art, and the general principles defined herein can be implemented in other embodiments without departing from the spirit or scope of the present application. Therefore, the present application will not be limited to the embodiments shown herein, but will conform to the widest range consistent with the principles and novel features applied for herein.

Claims

1. A phosphorylated antigen at Ser23 site of PGAM1 protein, characterized in that: The phosphorylated antigen is a phosphorylated polypeptide, the amino acid sequence of the phosphorylated polypeptide is shown in SEQ ID NO.1, wherein the phosphorylation site of the phosphorylated polypeptide is serine; The phosphorylation site of the phosphorylated polypeptide is site 23 of the PGAM1 protein.

2. A method for preparing the phosphorylated antigen according to claim 1, characterized in that: The method comprises: Taking site 23 of the PGAM1 protein as a base point, a preset number of amino acid groups are selected along the upstream or downstream direction on the amino acid sequence of the PGAM1 protein as shown in SEQ ID NO. 2 to obtain multiple groups of preset antigens; Using an immune epitope database to analyze and screen multiple groups of preset antigens to obtain the best antigen; Phosphorylating the optimal antigen to obtain a phosphorylated polypeptide; Performing protein coupling on the phosphorylated polypeptide to obtain a phosphorylated antigen; The preset number is 2 to 5.

3. A method for preparing a phosphorylated antibody, characterized in that: The method comprises: Immunizing an animal model with the phosphorylated antigen according to claim 1 to a preset antiserum titer to obtain an antiserum sample; According to the amino acid sequence of the PGAM1 protein shown in SEQ ID NO.2, a phosphorylated polypeptide: NRFS(p)GWY and a non-phosphorylated polypeptide: NRFSGWY were synthesized respectively, and then protein coupling was performed to obtain phosphorylated antigen and non-phosphorylated antigen; The antiserum sample is purified using the phosphorylated antigen and the non-phosphorylated antigen respectively to obtain the phosphorylated antibody.

4. The method according to claim 3, characterized in that The preset antiserum titer is ≥1:32000.

5. The method according to claim 3, characterized in that: The number of immunizations is ≥ 4 times.

6. The method according to claim 3, characterized in that The method of purifying the antiserum sample by using the phosphorylated antigen and the non-phosphorylated antigen to obtain the phosphorylated antibody comprises the following steps: Using the phosphorylated antigen to affinity purify the antiserum sample once to obtain a crude phosphorylated antibody; The crude phosphorylated antibody is subjected to secondary affinity purification using the non-phosphorylated antigen to obtain the phosphorylated antibody.

Citation Information

Patent Citations

  • Markers for differential diagnosis and methods of use thereof

    CN1751128A

  • Autoantibodies for protein antigens as markers for cancer of gingivo-buccal complex

    WO2008099419A2